Phio Pharmaceuticals Launches Substantial $6.36M At-The-Market Offering, Potentially Diluting Shares by Over 40%
Summary
Phio Pharmaceuticals has launched a substantial $6.36 million At-The-Market offering, which could significantly dilute existing shareholders but provides essential capital for advancing its lead clinical program and general operations.
Key Events
-
Launches At-The-Market (ATM) Offering
Phio Pharmaceuticals Corp. has entered into an At-The-Market offering agreement to sell up to $6.36 million of its common stock through H.C. Wainwright & Co., LLC.
-
Significant Potential Dilution
The offering could result in the issuance of approximately 4.97 million new shares, representing a potential dilution of over 40% to the current 11.62 million outstanding shares, based on a reference price of $1.28 per share.
-
Proceeds to Fund Clinical Development and Working Capital
Net proceeds from the offering are intended to fund the development of PH-762 in an expected Phase 2b/3 clinical trial for cutaneous squamous cell carcinoma, other development activities, and general working capital needs.
-
Maximized Under S-3 Public Float Rule
The $6.36 million offering amount is the maximum permitted under General Instruction I.B.6 of Form S-3, which limits sales to one-third of the company's public float when it is below $75 million.
Analysis
Phio Pharmaceuticals Corp. has launched a significant At-The-Market (ATM) offering to sell up to $6.36 million of common stock. This offering, detailed in the prospectus supplement, represents a substantial capital raise for the company, potentially increasing outstanding shares by over 40% based on the last reported sale price of $1.28 per share on April 2, 2026. The proceeds are earmarked for critical funding, including the development of its lead drug candidate PH-762 in an expected Phase 2b/3 clinical trial and general working capital. While highly dilutive for existing shareholders, this capital infusion is crucial for a clinical-stage biopharmaceutical company, especially following previous capital raises that resolved going concern doubts, as noted in the recent 10-K.
At the time of this filing, PHIO was trading at $1.24 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $15.1M. The 52-week trading range was $0.81 to $4.19. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.